Clinical Trials Logo

Hepatitis B, Chronic clinical trials

View clinical trials related to Hepatitis B, Chronic.

Filter by:

NCT ID: NCT00661076 Completed - Clinical trials for Hepatitis B, Chronic

ADVANCE Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) + Adefovir Dipivoxil in Patients With Hbe(-) Chronic Hepatitis B

Start date: August 2008
Phase: Phase 3
Study type: Interventional

This 3 arm study will compare the efficacy and safety of combination therapy with PEGASYS + adefovir dipivoxil (ADV) versus PEGASYS monotherapy, in HBeAg-negative chronic hepatitis B patients.Patients will be randomized to receive 1)PEGASYS 180 micrograms sc weekly + ADV 10mg po daily for 48 weeks, followed by ADV 10mg po monotherapy for an additional 48 weeks, and a further 48 week treatment-free follow-up, 2)PEGASYS 180 micrograms sc weekly + ADV 10mg po daily for 48 weeks, followed by a 96 week treatment-free follow-up, or 3)PEGASYS 180 micrograms sc monotherapy weekly for 48 weeks, followed by a 96 week treatment-free follow-up. The anticipated time on study treatment is 1-2 years, and the target sample size is <100 individuals.

NCT ID: NCT00651209 Completed - Clinical trials for Hepatitis B, Chronic

A Single-arm Study Evaluating the Efficacy and Safety of Telbivudine With or Without add-on Tenofovir in Adults With HBeAg-positive Chronic Hepatitis B (CHB)

Start date: February 2008
Phase: Phase 4
Study type: Interventional

This study will evaluate the use of telbivudine for patients with HBeAg-positive CHB with an option to intensify treatment at Week 24 by adding tenofovir for patients who do not achieve HBV DNA non-detectability.

NCT ID: NCT00646503 Completed - Clinical trials for Hepatitis B, Chronic

Prospective Exploratory Study to Evaluate the Safety and Efficacy of Telbivudine in the Fifth Year of Treatment in Chinese Patients With Compensated Chronic Hepatitis B

Start date: March 2008
Phase: Phase 4
Study type: Interventional

This study will explore efficacy and safety of Telbivudine in the fifth year of treatment.

NCT ID: NCT00645736 Completed - Chronic Hepatitis B Clinical Trials

CHARM: Chronic Hepatitis B Antihepadnaviral Resistance Mutation Study

CHARM
Start date: February 2008
Phase: N/A
Study type: Observational

This study has the aim of describing viral mutation profiles in patients diagnosed with chronic hepatitis B receiving antihepadnaviral therapy.

NCT ID: NCT00641082 Completed - Clinical trials for HBeAg(-) Chronic Hepatitis B With Compensated Liver Function

A Double-Blind Randomized Clinical Trial Comparing the Safety and Antiviral Activity of 48-week Clevudine and Adefovir Dipivoxil in HBeAg(-) Chronic Hepatitis B With Compensated Liver Function

Start date: February 2008
Phase: Phase 4
Study type: Interventional

A double-blind randomized, parallel, multicenter with 48 weeks of treatment period. The purpose of this study is to compare the safety and antiviral activity of 48-week Clevudine and Adefovir dipivoxil in HBeAg(-) Chronic Hepatitis B with compensated liver function.

NCT ID: NCT00640588 Completed - Clinical trials for Hepatitis B, Chronic

Prospective Exploratory Study to Describe Hepatitis B Virus (HBV) Kinetics During Treatment With Telbivudine

EBEREST
Start date: March 2008
Phase: Phase 3
Study type: Interventional

This study will explore HBV kinetics in CHB patients during the first 24 weeks of treatment with telbivudine

NCT ID: NCT00637663 Completed - Clinical trials for Hepatitis B, Chronic

Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable Hepatitis B Virus DNA

Start date: February 2008
Phase: Phase 4
Study type: Interventional

This is a randomized, open-labelled, prospective 96-week study comparing the antiviral efficacy and safety of switching to entecavir 0.5mg QD from lamivudine versus maintaining lamivudine 100mg QD treatment in CHB patients currently receiving lamivudine monotherapy.

NCT ID: NCT00635310 Recruiting - Chronic Hepatitis B Clinical Trials

Safety Profiles of Liver Biopsy in Hemodialysis Patients With Chronic Viral Hepatitis Pre-treated With Vasopressin

Start date: January 2005
Phase: N/A
Study type: Interventional

Percutaneous liver biopsy (PLB) is the gold standard for grading necroinflammation and staging fibrosis in patients with chronic viral hepatitis. Whether the use of 1-deamino-8-D-arginine vasopressin (DDAVP) before PLBs in hemodialysis (HD) patients with chronic viral hepatitis has comparable safety profiles to those with normal renal function (NRF) has not been evaluated in prospective studies.

NCT ID: NCT00625560 Completed - Clinical trials for Hepatitis B, Chronic

Continuing Lamivudine vs Switching to Entecavir in Patients With Detectable HBV DNA

Start date: February 2008
Phase: Phase 4
Study type: Interventional

This is a randomized, open-labelled, prospective 96-week study comparing the antiviral efficacy and safety of switching to entecavir 1 mg QD from lamivudine versus maintaining lamivudine 100 mg QD treatment in HBV-infected subjects currently receiving lamivudine monotherapy.

NCT ID: NCT00625339 Completed - Clinical trials for Hepatitis B, Chronic

Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable HBV DNA

Start date: February 2008
Phase: Phase 4
Study type: Interventional

This is a randomized, open-labelled, prospective 96-week study comparing the antiviral efficacy and safety of switching to entecavir 0.5mg QD from lamivudine versus maintaining lamivudine 100mg QD treatment in CHB patients currently receiving lamivudine monotherapy.